tbuckley/cabot-search huggingface dataset:
Clinical Guidelines for Management of Acne Vulgaris
Authors: Vincent Descamps
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?
Authors: Rachel J Cook, Zhiwei Wang, Mukta Arora, Hillard M. Lazarus, Kimberly A. Kasow, Martin A. Champagne, Wael Saber, Koen M. Van Besien, Gregory A. Hale, Edward A. Copelan, Mohamed Elmongy, Naoto T Ueno, Biljana N. Horn, Shimon Slavin, Edward A. Stadtmauer
Journal: Blood (2011)
Embigin Regulates HSPC Homing and Quiescence and Acts As a Cell Surface Marker for a Niche Factor-Enriched Subset of Osteolineage Cells
Authors: Lev Silberstein, Peter V. Kharchenko, Youmna Sami Kfoury, Francois Mercier, Raphael Turcotte, Charles P. Lin, Ninib Baryawno, Nicolas Severe, Tiffany Tate, Jonathan Hoggatt, David T. Scadden
Journal: Blood (2015)
Dual Production of IL-2 and IFN-Gamma by CMV-Specific CD8+ T-Cells Is a Hallmark of Their Ability to Control CMV Reactivation in Patients After Hematopoietic Stem Cell Transplantation,
Authors: Tomas Kalina, Ladislav Krol, Jan Stuchly, Petra Keslova, Petr Hubacek, Ondrej Pelak, Petr Sedlacek, Jan Stary, Ondrej Hrusak
Journal: Blood (2011)
Reduced Intensity Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Does the Conditioning Matter?.
Authors: Louis Terriou, Zina Chir, Helene Esperou, Jean-Michel Boiron, Jean-Paul Vernant, Nicole Gratecos, Mauricette Michalet, Noel Milpied, Jean-Pierre Jouet, Ibrahim Yakoub-Agha
Journal: Blood (2007)
Distinct IL-4 Intracellular Signaling in Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma: Novel Opportunities for Therapeutic Interventions.
Authors: Izidore S. Lossos, XiaoQing Lu, Feiying Ding, Manuel Rosado, Ash A. Alizadeh, Hovav Nechushtan
Journal: Blood (2004)
Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23
Authors: Vera Grossmann, Alexander Kohlmann, Susanne Schnittger, Sandra Weissmann, Sabine Jeromin, Jennifer Kienast, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2012)
Genetic Determinants of the Definitive Hematopoietic Stem/Progenitor Cell Compartment
Authors: Kirby D Johnson, Xin Gao, Rajendran Sanalkumar, Amy P Hsu, Myung-Jeom Ryu, Jinyong Wang, Meghan E Boyer, Yangang Liu, Katherine R Calvo, Sunduz Keles, Jing Zhang, Steven M. Holland, Emery H Bresnick
Journal: Blood (2012)
Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia.
Authors: Joseph Brandwein, David Hedley, Sue Chow, Aaron D. Schimmer, Karen WL Yee, Andre Schuh, Vikas Gupta, Mark D. Minden
Journal: Blood (2009)
Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.
Authors: George Ansstas, Waseem Touma, Camille Adeimy, Gao Feng, Peter Westervelt, Camille N. Abboud, Geoffrey L. Uy, Keith E. Stockerl-Goldstein, Amanda Cashen, John F. DiPersio, Ravi Vij
Journal: Blood (2010)
Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease
Authors: Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Sonia Vallet, Noopur Raje
Journal: Blood (2012)
AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid.
Authors: Federico Mingozzi, Marcela V. Maus, Denise E. Sabatino, Daniel J. Hui, John E.J. Rasko, Margaret V. Ragni, Catherine Scott Manno, Hildegund C.J. Ertl, Katherine A. High
Journal: Blood (2006)
A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Frederic J. Reu, Jason Valent, Ehsan Malek, Ronald M. Sobecks, Beth M Faiman, Kimberly Hamilton, Jamie Elberson, Sherry Fada, Hien K. Liu, Christy Samaras, Mitchell R. Smith
Journal: Blood (2015)
EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),
Authors: Aziz Nazha, Elias Jabbour, Jorge E. Cortes, Susan O'Brien, Jenny Shan, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, Hagop M. Kantarjian
Journal: Blood (2011)
Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,
Authors: Chadi Nabhan, Sonali M. Smith, Irene Helenowski, Erika Ramsdale, Reem Karmali, Benjamin Parsons, Josephine L. Feliciano, Britt E. Hanson, Scott E. Smith, Annette Larsen, June M. McKoy, Stephanie A. Gregory, Andrew M. Evens
Journal: Blood (2011)
Reply
Authors: Feng Su, George N. Ioannou
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. REPLY: We appreciate the correspondence by Dr. O'Brien and colleagues examining virological relapse rates according to IFNL4 ("IL28B") genotype. Their analysis is an extension of a previous report demonstrating that patients in the ION‐3 trial with non‐CC IL28B genotypes had lower sustained virological response (SVR) rates in the 8‐week treatment arms (CC, 98.2%; CT, 95.1%; TT, 90.0%) when SVR was recalculated excluding patients with missing outcome data.1 In their current report, they incorporate patients from the ION‐4 trial and conclude that relapse rates are higher in patients with IL28B CT (relative risk [RR], 2.74; 95% confidence interval [CI], 0.74‐10.17) and TT (RR, 4.58; 95% CI, 1.26‐16.56) genotypes compared to the CC genotype. The researchers suggest that IL28B genotype may explain disparities in SVR between black and nonblack patients treated with direct‐acting antivirals (DAAs), particularly in the setting of shortened treatment duration. The researchers also suggest that IL28B genotype testing might be helpful in determining appropriate DAA regimen and duration. We would like to highlight the following important considerations: It is very unlikely that IL28B polymorphisms explain the entire difference in response to DAAs between black and white patients. Although it is probably true that among patients treated with 8 weeks of ledipasvir/sofosbuvir (LDV/SOF), those with unfavorable IL28B genotype polymorphisms have lower SVR and higher relapse rate, the real question is whether the SVR would improve with extension of treatment to 12 weeks. Is there a statistically significant improvement in SVR when comparing 12 weeks versus 8 weeks of LDV/SOF monotherapy among treatment‐naïve, genotype‐1‐infected patients without cirrhosis with a baseline viral load of <6 million, who have a given IL28B genotype (CC or CT or TT)? When determining whether 8 weeks of LDV/SOF monotherapy is adequate or not, we would suggest that perhaps the on‐treatment viral response (e.g., the response at week 4 of treatment) would likely be a better, more‐efficient, and less‐expensive predictor than a series of genetic and nongenetic baseline predictors, given that the on‐treatment response likely incorporates the cumulative influence of all these known and unknown baseline predictors. Further research is required to investigate this.
Reactive Oxygen Species Level and GPX3 Expression in Human CD34+CD38− Progenitors Harvested From Cord Blood, Adult Bone Marrow and Peripheral Blood
Authors: Christine Vignon, Sebastien Lachot, Yves Levern, Beatrice Herault, Philippe Rosset, Franck Perrotin, Emmanuel Gyan, Jorge Domenech, Olivier Herault
Journal: Blood (2012)
Diffuse Large B-Cell Lymphoma with Extra BCL-2 Gene Signals Detected by FISH Analysis Is Associated with “Non-Germinal Center Phenotype” Defined by Immnohistochemistry.
Authors: Shigeru Kusumoto, Yukio Kobayashi, Naohiro Sekiguchi, Kazuki Tanimoto, Yasushi Onishi, Yukiko Yokota, Takashi Watanabe, Akiko Maeshima, Takashi Ishida, Hiroshi Inagaki, Yoshihiro Matsuno, Ryuzo Ueda, Kensei Tobinai
Journal: Blood (2004)
Direct Comparison of Wharton Jelly and Bone Marrow Derived Mesenchymal Stromal Cells to Enhance Engraftment of Cord Blood CD34+ Transplants
Authors: Mark van der Garde, Melissa Van Pel, Jose Millan Rivero, Alice de Graaf-Dijkstra, Manon Slot, Yoshiko Kleinveld, Suzanne Watt, Helene Roelofs, Jaap Jan Zwaginga
Journal: Blood (2015)
Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy
Authors: Samer Bayda, Mohamad Hadla, Stefano Palazzolo, Vinit Kumar, Isabella Caligiuri, Emmanuele Ambrosi, Enrico Pontoglio, Marco Agostini, Tiziano Tuccinardi, Alvise Benedetti, Pietro Riello, Vincenzo Canzonieri, Giuseppe Corona, Giuseppe Toffoli, Flavio Rizzolio
Journal: Journal of Controlled Release (2017)
Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.
Authors: Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Shaughnessy, John Crowley
Journal: Blood (2005)
The Combination of Cyclosporine and Mycophenolate Mofetil Is Less Effective Than Cyclosporine and Methotrexate in the Prevention of Acute Graft-Versus Host Disease after Allogeneic Stem Cell Transplantation from Unrelated Donors
Authors: Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Arnon Nagler, Avichai Shimoni
Journal: Blood (2015)
Activation of the JNK Pathway Mediates Chemoresistance in T-Cell Acute Lymphoblastic Leukemia by Phosphorylation and Proteosomal Degradation of BimEL.
Authors: Kam Tong Leung, Karen Kwai Har Li, Samuel Sai Ming Sun, Paul Kay Sheung Chan, Yum Shing Wong, Vincent Eng Choon Ooi, Lawrence Chi Ming Chiu
Journal: Blood (2007)
IKKα controls ATG16L1 degradation to prevent ER stress during inflammation
Authors: Michaela A. Diamanti, Jalaj Gupta, Moritz Bennecke, Tiago De Oliveira, Mallika Ramakrishnan, Anne K. Braczynski, Benjamin Richter, Petra Beli, Yinling Hu, Maya Saleh, Michel Mittelbronn, Ivan Dikic, Florian R. Greten
Journal: The Journal of Experimental Medicine (2017)

Inhibition of the IκB kinase complex (IKK) has been implicated in the therapy of several chronic inflammatory diseases including inflammatory bowel diseases. In this study, using mice with an inactivatable IKKα kinase (IkkαAA/AA), we show that loss of IKKα function markedly impairs epithelial regeneration in a model of acute colitis. Mechanistically, this is caused by compromised secretion of cytoprotective IL-18 from IKKα-mutant intestinal epithelial cells because of elevated caspase 12 activation during an enhanced unfolded protein response (UPR). Induction of the UPR is linked to decreased ATG16L1 stabilization in IkkαAA/AA mice. We demonstrate that both TNF-R and nucleotide-binding oligomerization domain stimulation promote ATG16L1 stabilization via IKKα-dependent phosphorylation of ATG16L1 at Ser278. Thus, we propose IKKα as a central mediator sensing both cytokine and microbial stimulation to suppress endoplasmic reticulum stress, thereby assuring antiinflammatory function during acute intestinal inflammation.
High Efficacy and Good Tolerability with Rituximab In Vivo Purging Followed by High Dose Chemotheraphy and Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in Non-Hodgkin’s Lymphoma (NHL).
Authors: Yuankai Shi, Sheng Yang, Xiaohong Han, Peng Liu, Xiaohui He, Jun Ma, Hanyun Ren, Xi’nan Cen, Shuyuan Zhou, Chun Wang
Journal: Blood (2004)
Omega-3 Fatty Acids Reduce the Number of Crisis and Steady State Hemolysis In Sickle Cell Disease
Authors: Iheanyi Okpala, Obike Ibegbulam, Augustine Duru, Sunday Ocheni, Ifeoma Emodi, Anthony Ikefuna, Umar Kangiwa, Isaac Asinobi, Anazoeze Madu, Augustine Okoye, Tessy Nwagha, Uche Oguonu, Ify Uamai, Obineche Agwu, Charles Nonyelum, Uche Anike, Kingsley Agu, Chukwudi Anigbo, Awele Chukwura, Ogechukwu Ugwu, S. Herrada
Journal: Blood (2010)
Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)
Authors: Victor M. Rivera, Qihong Xu, Lori Berk, Jeffrey Keats, Scott Wardwell, Frank Wang, William C. Shakespeare, Tim Clackson
Journal: Blood (2008)
Prognostic Impact of p190 and p210 Co-Expression in Early Molecular Response in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosin Kinase Inibitors
Authors: Gioacchino Catania, Nicol Trincheri, Enrico Marco Gottardi, Giulia Limberti, Marco Ladetto, Federico Monaco, Massimo Pini, Valentina Giai
Journal: Blood (2016)
Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide
Authors: Dana E Rollison, Kenneth H. Shain, Ji-Hyun Lee, Shalaka S Hampras, Kate Fisher, Najla H Al Ali, Eric Padron, Jeff E Lancet, Marta Olesnyckyj, Laurie Kenvin, Robert D. Knight, William Dalton, Alan F. List, Rami Komrokji
Journal: Blood (2014)
The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis
Authors: Fortunato Morabito, Giovanna Cutrona, Anna Grazia Recchia, Sonia Fabris, Serena Matis, Monica Colombo, Sabrina Bossio, Massimo Gentile, Carlotta Massucco, Laura De Stefano, Stefano Molica, Caterina Musolino, Fiorella Ilariucci, Gianluca Festini, Francesco Di Raimondo, Pierfrancesco Tassone, Antonino Neri, Claudio Tripodo, Manlio Ferrarini
Journal: Blood (2012)
Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats
Authors: Reinhard Stidl, Juergen Siekmann, Sean M Culbertson, Tony Vinson, Antoni Kozlowski, Xiaoming Shen, Mary J Bossard, Hanspeter Rottensteiner, Barbara Dietrich, Chyung Cook, Peter L Turecek, Hartmut J. Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Eva-Maria Muchitsch
Journal: Blood (2011)
Clinical Laboratory Medicine.
Journal: Annals of Internal Medicine (1969)

annum, and three clerks each at $1,800 per annum, and three messengers each at $900 per annum.Section 3.That the director and specialists, it necessary for the proper discharge of their duties, may place themselves in communication with state and municipal and other officials of this and other countries.Section 4. That for the proper equipment of and carrying on the work of said laboratory, the temporary
Rhnull Syndrome: Identification of a Novel Mutation in RHce Gene.
Authors: Marion E. Reid, Karina A. Rosa, Vivien I. Powell, Christine Lomas-Francis, Fernando F. Costa, Servio T. Stinghen, Alexandra M. Watanabe, Edna K. Carboni, Joseani P. Baldon, Maria Marta F. Jucksch, Lilian Castilho
Journal: Blood (2004)
Killer Immunoglobulin-Like Receptor and NOD2/CARD15 Polymorphisms Independently Influence Survival after Allogeneic Hematopoietic Stem Cell Transplanation.
Authors: Sebastian Giebel, Aleksandra Holowecka-Goral, Izabela Nowak, Tomasz Czerw, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Joanna Dziaczkowska, Miroslaw Markiewicz, Iwona Wylezol, Elzbieta Pietruszka, Piotr Kusnierczyk, Jerzy Holowiecki
Journal: Blood (2007)
Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.
Authors: Rachel B. Salit, Steven Z. Pavletic, Daniel H. Fowler, Jennifer Wilder, Kelly Bryant, Seth M. Steinberg, Frances T. Hakim, Michael R. Bishop
Journal: Blood (2010)
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas
Authors: Yu Sun, John A Alberta, Catherine Pilarz, David Calligaris, Emily J Chadwick, Shakti H Ramkissoon, Lori A Ramkissoon, Veronica Matia Garcia, Emanuele Mazzola, Liliana Goumnerova, Michael Kane, Zhan Yao, Mark W Kieran, Keith L Ligon, William C Hahn, Levi A Garraway, Neal Rosen, Nathanael S Gray, Nathalie Y Agar, Sara J Buhrlage, Rosalind A Segal, Charles D Stiles
Journal: Neuro-Oncology (2016)

Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs). However, first-generation RAF inhibitors approved for adult melanoma have poor blood-brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer. These drugs (type I antagonists that target the "DFG-in" conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA.
Treatment of reactive hypoglycemia with the macrobiotic Ma-pi 2 diet as assessed by continuous glucose monitoring: The MAHYP randomized crossover trial
Authors: Andreea Soare, Yeganeh Manon Khazrai, Lucia Fontana, Rossella Del Toro, Maria Concetta Lazzaro, Claudia Di Rosa, Antonia Buldo, Elvira Fioriti, Ernesto Maddaloni, Silvia Angeletti, Antonio Di Mauro, Rosaria Gesuita, Edlira Skrami, Dario Tuccinardi, Sara Fallucca, Mario Pianesi, Paolo Pozzilli
Journal: Metabolism (2017)
Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.
Authors: G.J.L. Kaspers, M. Zimmermann, D. Reinhardt, B. Gibson, R. Tamminga, O. Aleinikova, H. Armendariz, M. Dworzak, S. Ha, L. Hovi, A. Maschan, A. Baruchel, Y. Bertrand, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, U. Creutzig
Journal: Blood (2009)
Identification and Functional Characterization of Telomerase RNA Variant Alleles in Japanese Patients with Aplastic Anemia or Myelodysplastic Syndrome.
Authors: Junko Takeuchi, Ly Hinh, Beauchamp Adam, Koiti Inokuchi, Fumiko Kosaka, Kazuhiro Sawaguchi, Yoshio Mitamura, Ayako Watanabe, Seiji Gomi, Hiroki Yamaguchi, Kazuo Dan
Journal: Blood (2006)
Coexistence of a Heterozygous JAK2(V617F) Mutation and a Secondary BCR-ABL Translocation within the Compartment of Committed Myeloid Progenitors in Chronic Idiopathic Myelofibrosis.
Authors: Martin Bornhaeuser, Brigitte Mohr, Uta Oelschlaegel, Peter Bornhauser, Swen Jacki, Gerhard Ehninger, Christian Thiede
Journal: Blood (2006)
Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy
Authors: Grace-Julia Okoroji, Leandro de Padua Silva, Rima M Saliba, Martin Korbling, McLaughlin Peter, Chitra Hosing, Paolo Anderlini, Amin Alousi, Marcos de Lima, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Luis Fayad, Felipe Samaniego, Nathan Fowler, Richard Champlin, Fredrick Hagemeister, Issa F Khouri
Journal: Blood (2010)
MicroRNA Expression Shows Inflammatory Dysregulation and Tumor‐Like Proliferative Responses in Joints of Patients With Postinfectious Lyme Arthritis
Authors: Robert B. Lochhead, Klemen Strle, Nancy D. Kim, Minna J. Kohler, Sheila L. Arvikar, John M. Aversa, Allen C. Steere
Journal: Arthritis & Rheumatology (2017)

Lyme arthritis (LA) is caused by infection with Borrelia burgdorferi and usually resolves following spirochetal killing with antibiotics. However, in some patients, arthritis persists after antibiotic therapy. To provide insights into underlying pathogenic processes associated with antibiotic-refractory LA (postinfectious LA), we analyzed differences in microRNA (miRNA) expression between LA patients with active infection and those with postinfectious LA.MicroRNA expression was assayed in synovial fluid (SF) from LA patients before and after oral and intravenous antibiotic therapy, and in synovial tissue obtained months after antibiotic therapy from patients with postinfectious LA. SF and tissue from patients with other forms of arthritis, such as rheumatoid arthritis (RA) and osteoarthritis, were used for comparison.SF from LA patients during active infection had marked elevations of white blood cells, particularly polymorphonuclear leukocytes, accompanied by elevated levels of microRNA-223 (miR-223). In contrast, SF from postantibiotic LA patients contained greater percentages of lymphocytes and mononuclear cells. SF from postantibiotic LA patients also exhibited marked inflammatory (miR-146a, miR-155), wound repair (miR-142), and proliferative (miR-17-92) miRNA signatures, and higher levels of these miRNAs correlated with longer arthritis duration. Levels of miR-146a, miR-155, miR-142, miR-223, and miR-17-92 were also elevated in synovial tissue in late postinfectious LA, and levels of let-7a were reduced, similar to RA.During active infection, miRNA expression in SF reflected an immune response associated with bacterial killing, while in postinfectious LA, miRNA expression in SF and synovial tissue reflected chronic inflammation, synovial proliferation, and breakdown of wound repair processes, showing that the nature of the arthritis was altered after spirochetal killing.
Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease
Authors: Tobias Suiter, Michael Laffan, Pier M. Mannucci, Christine L. Kempton, Edward H Romond, Amy D. Shapiro, Ingvild Birschmann, Joan Cox Gill, Margaret V. Ragni, Peter Turecek, Bruce M. Ewenstein, VrWF Study Team Baxter BioScience
Journal: Blood (2010)
A novel and effective delivery method for polyglycolic acid sheets to post-endoscopic submucosal dissection ulcers
Authors: Toshitatsu Takao, Yoshitaka Takegawa, Hiroyuki Ono, Madoka Takao, Shiro Oka, Noriko Shinya, Hiromu Kutsumi, Takeshi Azuma
Journal: Endoscopy (2017)

<b>Background and aims</b> Shielding methods for post-endoscopic submucosal dissection (ESD) ulcers have delivery-related problems. We developed an enveloped device for this purpose and evaluated its usefulness. <b>Materials and methods</b> Polyglycolic acid (PGA) sheets were delivered to six 3.0-cm ulcers in two resected porcine stomachs and six 5.0-cm ulcers in another three stomachs. In the regular method group, small PGA sheets were delivered via forceps. In the novel method group, a large PGA sheet was delivered via the new device. The methods were compared in terms of time, and macroscopic and histological findings of the ulcer floor. <b>Results</b> The median time required to cover a 3.0-cm ulcer was 0.39 min/cm<sup>2</sup> in the novel method group and 1.03 min/cm<sup>2</sup> in the regular method group (<i>P</i> = 0.03), and to cover a 5.0-cm ulcer was 0.38 min/cm<sup>2</sup> and 0.85 min/cm<sup>2</sup>, respectively (<i>P</i> = 0.03). In the novel method group, the PGA sheets were in close contact, fully covering the ulcer floor. In the regular method group, the sheets were partly elevated from the ulcer floor. <b>Conclusions</b> This novel technique seems promising in this preliminary study.